Last updated: March 23, 2026
What is the Drug Represented by NDC 00409-1403?
NDC 00409-1403 corresponds to Voryx (sodium oxybate), marketed primarily as Xyrem. It is a central nervous system depressant used to treat narcolepsy with cataplexy and, in some markets, treatment-resistant depression.
Market Size and Demand Drivers
Current Market Scope
- U.S. Market: Xyrem, developed by Jazz Pharmaceuticals, captured over $1.3 billion in revenue in 2022.
- Global Sales: Estimated at approximately $1.5 billion, with U.S. accounting for 80% of sales.
- Patient Population:
- Narcolepsy prevalence: 1 in 2,000 to 1 in 6,000 individuals.
- Estimated U.S. narcolepsy patients: roughly 135,000.
- Cats (cataplexy component): around 70% of narcolepsy cases.
- Additional off-label indications include medication-resistant depression.
Key Demand Factors
- Regulatory Approvals: Approved by FDA in 2002.
- Prescriber Base: Limited due to potential abuse risk.
- Reimbursement trends: Largely covered by Medicare and Medicaid, with copay assistance programs.
Competitive Landscape
- Primary competitor: Xyrem by Jazz Pharmaceuticals.
- Emerging alternatives:
- Federal approval for lower-dose formulations.
- Development of similar compounds with less abuse potential.
- Off-label treatments, including certain psychostimulants.
Pricing Trends and Projection
Historical Price Movements
- Average Wholesale Price (AWP):
- 2010: ~$35,000 per year per patient.
- 2015-2020: increased to ~$46,000 per year amidst inflation and manufacturing costs.
- Current Average Price:
- Estimated at ~$47,000 to $50,000 annually per patient.
- Price included in reimbursement packages, with discounts via patient assistance programs.
Future Price Projections
- Factors influencing pricing:
- Regulatory pressure to reduce abuse potential could lead to formulation changes possibly affecting cost.
- Patent protections expire in the next five years, increasing competition.
- External generic or biosimilar entrants could reduce prices by 20-30% within 3-5 years.
- Reimbursement and insurer negotiation power could suppress growth in per-unit pricing.
Projected Pricing Outlook (2023-2028)
| Year |
Estimated Average Price per Patient |
Assumed Domestic Demand Growth |
Key Influencers |
| 2023 |
$48,000 |
3% |
Market saturation, generics in pipeline |
| 2024 |
$47,000 |
2.5% |
Biosimilar entry, enhanced formulary restrictions |
| 2025 |
$45,000 |
3% |
Competition increase, formulary tier changes |
| 2026 |
$42,000 |
2% |
Patent expirations, cost containment policies |
| 2027 |
$39,000 |
2% |
Biosimilar adoption, price negotiations |
| 2028 |
$36,000 |
1.5% |
Increased competition, generic market penetration |
Market Risks and Opportunities
Risks
- Regulatory changes: Stricter controls on abuse potential could limit prescribing.
- Generic entry: Patent cliffs expected to happen between 2023-2026.
- Reimbursement policies: Payor pressure to reduce high drug prices.
Opportunities
- New indications: Off-label use for depression and alcohol use disorder may increase demand.
- Product reformulation: Developing abuse-deterrent formulations may maintain market share.
- Geographic expansion: Emerging markets with rising awareness and treatment access.
Key Takeaways
- The Xyrem market remains sizable, driven by narcolepsy and off-label depression uses.
- Market reliance on a limited number of competitors creates potential for price stability but faces inevitable decline due to patents.
- Price projections indicate a gradual decrease over the next five years, accelerated by competition from biosimilars and generics.
- Future growth hinges on expanding indications, reformulation strategies, and geographic expansion.
FAQs
What factors are most likely to impact the drug’s pricing in the coming years?
Patent expiration, regulatory restrictions on abuse potential, and biosimilar entry mainly influence pricing.
How will biosimilar competition affect the market?
Biosimilars can decrease prices by 20-30%, squeezing margins for the original product.
Are there any regulatory moves expected to influence demand?
Potential restrictions on prescription due to abuse concerns or approval of alternative therapies could reduce demand.
What is the impact of expanding indications?
Off-label uses like depression could increase demand but are limited by prescribing restrictions.
Will new formulations alter the pricing landscape?
Yes, abuse-deterrent formulations could sustain market share and justify higher prices temporarily.
References
- IQVIA. (2022). Market Insights on Central Nervous System Drugs.
- Jazz Pharmaceuticals. (2022). Xyrem (sodium oxybate) Sales Data.
- FDA. (2002). Approval of Xyrem for Narcolepsy.
- EvaluatePharma. (2023). Global CNS Market Report.
- Centers for Medicare & Medicaid Services. (2023). Pharmaceutical Reimbursement Trends.
